嗜铬细胞瘤/副神经节瘤免疫微环境

doi:10.16352/j.issn.1001-6325.2024.06.0742

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (6): 742-747.doi: 10.16352/j.issn.1001-6325.2024.06.0742

• 特邀专题：肾上腺肿瘤的发病机制 • 上一篇下一篇

嗜铬细胞瘤/副神经节瘤免疫微环境

周玥, 童安莉^*

中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室,北京 100730

收稿日期:2024-03-31 修回日期:2024-04-23 出版日期:2024-06-05 发布日期:2024-05-24
通讯作者: ^*tonganli@hotmail.com
基金资助:
中央高水平医院临床研究专项(2022-PUMCH-C-028);中国医学科学院医学与健康科技创新工程(2021-I2M-C&T-B-002)

Immune microenvironment of pheochromocytomas and paragangliomas

ZHOU Yue, TONG Anli^*

Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China

Received:2024-03-31 Revised:2024-04-23 Online:2024-06-05 Published:2024-05-24
Contact: ^*tonganli@hotmail.com

摘要/Abstract

摘要： 嗜铬细胞瘤/副神经节瘤(PPGLs)是罕见的神经内分泌肿瘤,遗传易感性高,其中SDHx突变为主的假性缺氧型肿瘤恶性潜能大。约10%~17%的PPGLs肿瘤会发生转移,转移性PPGLs缺乏有效的治疗,预后差。免疫微环境与肿瘤的发生发展密切相关,能够预测患者预后及其对免疫检查点抑制剂治疗的反应。目前已有部分研究初步描绘了PPGLs免疫图谱。本文主要就PPGLs免疫微环境中各类免疫细胞浸润情况、免疫检查点分子的表达及其与患者基因背景及肿瘤转移的关系进行综述,以更好地理解肿瘤免疫逃逸机制,并为转移性PPGLs患者寻找新的治疗方案提供思路。

关键词: 嗜铬细胞瘤/副神经节瘤, 转移性嗜铬细胞瘤/副神经节瘤, 肿瘤免疫微环境, 免疫细胞, 免疫检查点

Abstract: Pheochromocytomas/Paragangliomas(PPGLs) are rare neuroendocrine tumors with a high hereditary predisposition. The pseudo-hypoxic PPGLs dominated by SDHx mutations show a higher potential of metastasis. Approximately 10%-17% of PPGLs develop metastasis and patients with metastatic diseases have restricted treatment options and a poor prognosis. Tumor immune microenvironment (TIME) plays a crucial role in the development and progression of tumors as well as predicting patients’ prognosis and their response to immune checkpoint inhibitors. Several studies have initially characterized the immune landscape of PPGLs. This review focuses on the infiltration of immune cells,the expression of immune checkpoints in the TIME of PPGLs and their relationships with genetics and metastasis of tumors in order to better understand the mechanisms of tumor immune evasion in PPGLs and provide insights to support novel treatment strategy for metastatic PPGLs.

Key words: pheochromocytomas/paragangliomas, metastatic pheochromocytomas/paragangliomas, tumor immune microenvironment, immune cell, immune checkpoint

中图分类号:

R586.9

周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.

ZHOU Yue, TONG Anli. Immune microenvironment of pheochromocytomas and paragangliomas[J]. Basic & Clinical Medicine, 2024, 44(6): 742-747.

参考文献 30

[1]	Hendry S,Salgado R,Gevaert T,et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Work-ing Group: Part 1: Assessing the host immune response,TILs in invasive breast carcinoma and ductal carcinoma in situ,metastatic tumor deposits and areas for further research[J]. Adv Anat Pathol,2017,24: 235-251.doi.org/10.1097/pap.0000000000000162.
[2]	Tufton N,Hearnden RJ,Berney DM,et al. The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas[J]. Endocr Relat Cancer,2022,29: 589-598.doi.org/10.1530/erc-22-0020.
[3]	Tamborero D,Rubio-Perez C,Muiños F,et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations[J]. Clin Cancer Res,2018,24: 3717-3728.doi.org/10.1158/1078-0432.Ccr-17-3509.
[4]	Thorsson V,Gibbs DL,Brown SD,et al. The immune landscape of cancer[J]. Immunity,2018,48: 812-830.e814.doi.org/10.1016/j.immuni.2018.03.023.
[5]	Jin B,Han W,Guo J,et al. Initial characterization of immune microenvironment in pheochromocytoma and paraganglioma[J]. Front Genet,2022,13: 1022131.doi.org/10.3389/fgene.2022.1022131.
[6]	Zethoven M,Martelotto L,Pattison A,et al. Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment[J]. Nat Commun,2022,13: 6262.doi.org/10.1038/s41467-022-34011-3.
[7]	Celada L,Cubiella T,San-Juan-Guardado J,et al. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype[J]. J Pathol,2023,259: 103-114.doi.org/10.1002/path.6026.
[8]	Gao X,Yamazaki Y,Pecori A,et al. Histopathological analysis of tumor microenvironment and angiogenesis in pheochromocytoma[J]. Front Endocr,2020,11: 587779.doi.org/10.3389/fendo.2020.587779.
[9]	Calsina B,Piñeiro-Yáñez E,Martínez-Montes ÁM,et al. Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma[J]. Nat Commun,2023,14: 1122.doi.org/10.1038/s41467-023-36769-6.
[10]	Gudgeon N,Munford H,Bishop E L,et al. Succinate uptake by T cells suppresses their effector function via inhibition of mitochondrial glucose oxidation[J]. Cell Rep,2022,40: 111193.doi.org/10.1016/j.celrep.2022.111193.
[11]	Ghosal S,Vanova KH,Uher O,et al. Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis[J]. Endocrine,2023,79: 171-179.doi.org/10.1007/s12020-022-03218-1.
[12]	Farhat NA,Powers JF,Shepard-Barry A,et al. A previously unrecognized monocytic component of pheochromocytoma and paraganglioma[J]. Endocr Pathol,2019,30: 90-95.doi.org/10.1007/s12022-019-9575-6.
[13]	Brazda P,Ruiz-Moreno C,Megchelenbrink WL,et al. Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas[J]. Front Oncol,2022,12: 965168.doi.org/10.3389/fonc.2022.965168.
[14]	Bornstein SR,Ehrhart-Bornstein M,González-Hernández J,et al. Expression of interleukin-1 in human pheochromocytoma[J]. J Endocrinol Invest,1996,19: 693-698.doi.org/10.1007/bf03349041.
[15]	Batchu S. Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas[J]. J Endocrinol Invest,2021,44: 1543-1546.doi.org/10.1007/s40618-020-01443-x.
[16]	Chen CX,Chen DN,Sun XL,et al. Identification of vital prognostic genes related to tumor microenvironment in pheochromocytoma and paraganglioma based on weighted gene co-expression network analysis[J]. Aging,2021,13: 9976-9990.doi.org/10.18632/aging.202754.
[17]	Wu JY,Huang TW,Hsieh YT,et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor[J]. Mol Cell,2020,77: 213-227.e215.doi.org/10.1016/j.molcel.2019.10.023.
[18]	Zhong X,Su T,Yang Y,et al. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic markers for pheochromocytomas and paragangliomas[J]. J Clin Endocr Metab,2023,108: 2230-2239.doi.org/10.1210/clinem/dgad149.
[19]	Hadrava Vanova K,Uher O,Meuter L,et al. PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma[J]. Front Oncol,2022,12: 1045517.doi.org/10.3389/fonc.2022.1045517.
[20]	Guo D,Zhao X,Wang A,et al. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas[J]. Hum Pathol,2019,86: 155-162.doi.org/10.1016/j.humpath.2018.10.041.
[21]	Pinato DJ,Black JR,Trousil S,et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response,immune evasion and malignant behavior[J]. Oncoimmunology,2017,6: e1358332.doi.org/10.1080/2162402x.2017.1358332.
[22]	Chen Y,Qian Y,Huang W,et al. Chronic stress promotes tumor immune evasion via the suppression of MHC-I expression and the upregulation of PD-L1[J]. Am J Cancer Res,2022,12: 5286-5299.
[23]	Hsu YR,Torres-Mora J,Kipp BR,et al. Clinicopathologi-cal,immunophenotypic and genetic studies of mediastinal paragangliomas[J]. Eur J Cardio-thoracic Surg,2019,56: 867-875.doi.org/10.1093/ejcts/ezz115.
[24]	Fischer A,Maccio U,Wang K,et al. PD-L1 and HIF-2α upregulation in head and neck paragangliomas after embolization[J]. Cancers,2023,15.doi.org/10.3390/cancers15215199.
[25]	Batchu S,Hakim A,Henry OS,et al. Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes[J]. J Endocrinol Invest,2022,45: 989-998.doi.org/10.1007/s40618-021-01729-8.
[26]	Kim S,Kim A,Shin JY,et al. The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types[J]. Sci Rep,2020,10: 9536.doi.org/10.1038/s41598-020-66449-0.
[27]	Jimenez C,Subbiah V,Stephen B,et al. Phase Ⅱ clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas[J]. Cancers,2020,12.doi.org/10.3390/cancers12082307.
[28]	Economides MP,Shah AY,Jimenez C,et al. A durable response with the combination of nivolumab and cabozan-tinib in a patient with metastatic paraganglioma: A case report and review of the current literature[J]. Front Endocr,2020,11: 594264.doi.org/10.3389/fendo.2020.594264.
[29]	Papewalis C,Kouatchoua C,Ehlers M,et al. Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma[J]. Mol Cell Endocrinol,2011,335: 69-77.doi.org/10.1016/j.mce.2010.05.021.
[30]	Uher O,Huynh TT,Zhu B,et al. Identification of immune cell infiltration in murine pheochromocytoma during combined mannan-BAM,TLR ligand,and anti-CD40 antibody-based immunotherapy[J]. Cancers,2021,13.doi.org/10.3390/cancers13163942.

嗜铬细胞瘤/副神经节瘤免疫微环境

Immune microenvironment of pheochromocytomas and paragangliomas

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 14

编辑推荐

Metrics

本文评价

[1]	李天翊, 张文倩, 陈映含, 周玥, 崔云英, 王宇, 童安莉. 嗜铬细胞瘤/副神经节瘤患者血NSE水平与临床特征的关系[J]. 基础医学与临床, 2024, 44(4): 533-538.
[2]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[3]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[4]	李昱阳, 李钊璇, 罗云萍, 陈翀. 小鼠乳腺癌干细胞免疫相关分子表达和免疫浸润的分析[J]. 基础医学与临床, 2022, 42(6): 876-882.
[5]	李钊璇, 罗云萍, 陈翀. 气液交互法培养小鼠来源的肿瘤类器官的建立及优化[J]. 基础医学与临床, 2022, 42(5): 782-787.
[6]	甘兹颖, 唐慧. 溶瘤病毒联合PD-1/PD-L1抑制剂的研究进展[J]. 基础医学与临床, 2022, 42(4): 651-655.
[7]	斯晓燕, 王汉萍, 张力, 王孟昭, 张晓彤. 免疫检查点抑制剂致细胞因子释放综合征1例[J]. 基础医学与临床, 2022, 42(11): 1764-1766.
[8]	张若曦, 韩冰. 免疫检查点抑制剂治疗骨髓增生异常综合征的研究进展[J]. 基础医学与临床, 2021, 41(8): 1210-1215.
[9]	梁冰, 罗后宙. 塞来昔布对膀胱癌细胞移植小鼠的治疗作用及机制[J]. 基础医学与临床, 2021, 41(2): 240-244.
[10]	余静, 刘可, 王海燕, 严军. 非甾体抗炎剂调控免疫细胞的研究进展[J]. 基础医学与临床, 2021, 41(12): 1833-1837.
[11]	李佳忆, 幸兵. 免疫检查点抑制剂相关自身免疫性垂体炎的研究进展[J]. 基础医学与临床, 2020, 40(3): 403-406.
[12]	刘喜波孙爱静王宁孙丽萍陈丽荣. 液基细胞技术在术前检测乳腺癌ER和PR中的应用[J]. 基础医学与临床, 2010, 30(7): 771-772.
[13]	冉亮凃刚王小毅赵聪任国胜. Y14和Upf1在人乳腺癌细胞表达增强 [J]. 基础医学与临床, 2009, 29(11): 1150-1154.
[14]	赵楠刘俊高鸿岑键昌庞江霞王廷华冯忠堂. 新生小鼠嗅鞘细胞的分离纯化和生物学特性[J]. 基础医学与临床, 2008, 28(5): 477-481.